Elan Corp. plc
Treasury Building
Lower Grand Canal Street
Dublin,
2
Ireland - Map
Phone: 353 1 709 4444
Fax: 353 1 709 4700
Web Site: http://www.elan.com
| Elan Corporation, plc operates as a neuroscience-based biotechnology company primarily in Ireland and the United States. It operates in two segments, Biopharmaceuticals and Elan Drug Technologies (EDT). The Biopharmaceuticals segment engages in the research, development, and commercial activities primarily in Alzheimers disease, Parkinsons disease, multiple sclerosis, Crohns disease, severe chronic pain, and infectious diseases. It offers Tysabri, an alpha 4 integrin antagonist for the treatment of relapsing forms of multiple sclerosis; Prialt for the management of severe chronic pain; Maxipime, an injectable cephalosporin antibiotic to treat serious and/or life-threatening infections; and Azactam, an injectable antibiotic to treat pneumonia, post-surgical infections, and septicemia. This segment, through collaboration with Biogen Idec, Inc., develops and markets Tysabri as a treatment for Crohns disease. It also develops ELND005, a small molecule therapeutic that acts by breaking down and preventing the aggregation of beta amlyoid fibrils in collaboration with Transition Therapeutics, Inc. In addition, Biopharmaceuticals segment, through collaboration with Wyeth, develops beta amyloid immunotherapies, including AAB-001 and ACC-001, which are in various stages of development for the treatment of Alzheimers disease. The EDT segment engages in the development and manufacture of drug optimization technologies. It also offers a range of services, which include formulation development, clinical trial management, analytical development, clinical trial material manufacturing, scale-up, product registration support, and supply chain management for client products. Elan Corporation sells its products primarily to drug wholesalers worldwide. It has a development agreement with Circ Pharma Limited to develop a chronotherapeutic formulation of Tramadol for the treatment of severe pain. The company was founded in 1969 and is headquartered in Dublin, Ireland. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. G. Kelly Martin , 50
Chief Exec. Officer and Exec. Director |
N/A
| N/A | Mr. Shane Cooke , 46
Chief Financial Officer, Exec. VP, Exec. Director and Head of Elan Drug Technologies |
$
1.04M |
$
0 | Mr. William F. Daniel , 57
Exec. VP and Company Sec. |
$
469.00K |
$
0 | Dr. Carlos V. Paya M.D, Ph.D, 50
Pres |
N/A
| N/A | Dr. Johannes Roebers Ph.D, 48
Head of Biologic Strategy Planning & Operations and Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
Profile
